Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M ^pro and cathepsin L

The main protease (M^pro) of SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic, is a key antiviral drug target. While most SARS-CoV-2 M^pro inhibitors have a γ-lactam glutamine surrogate at the P1 position, we recently discovered several M^pro inhibitors have hydrophobic moieties at the P1 site, including calpain inhibitors II/XII, which are also active against human cathepsin L, a host-protease that is important for viral entry. To determine the binding mode of these calpain inhibitors and establish a structure-activity relationship, we solved X-ray crystal structures of M^pro in complex with calpain inhibitors II and XII, and three analogues of GC-376, one of the most potent M^pro inhibitors in vitro. The structure of M^pro with calpain inhibitor II confirmed the S1 pocket of M^pro can accommodate a hydrophobic methionine side chain, challenging the idea that a hydrophilic residue is necessary at this position. Interestingly, the structure of calpain inhibitor XII revealed an unexpected, inverted binding pose where the P1' pyridine inserts in the S1 pocket and the P1 norvaline is positioned in the S1' pocket. The overall conformation is semi-helical, wrapping around the catalytic core, in contrast to the extended conformation of other peptidomimetic inhibitors. Additionally, the structures of three GC-376 analogues UAWJ246, UAWJ247, and UAWJ248 provide insight to the sidechain preference of the S1', S2, S3 and S4 pockets, and the superior cell-based activity of the aldehyde warhead compared with the α-ketoamide. Taken together, the biochemical, computational, structural, and cellular data presented herein provide new directions for the development of M^pro inhibitors as SARS-CoV-2 antivirals.

Keywords: 3CL protease; COVID-19; GC-376; SARS-CoV-2; boceprevir; calpain inhibitors; main protease.